PerSe Technologies News

The report also includes earnings and earnings per share, margin and return ratios, financial strength, growth ratios, dayA's sales outstanding, dayA's outstanding inventory, cash and short-term investments per share and total common shares outstanding.

Nov 19, 2009 - Pluristem Therapeutics Inc. today announced that it will present three month follow-up data from the first patient to receive PLX-PAD at both the 1st Annual Conference of the German-Israeli Life Science Committee at the Life Science Center in Dsseldorf, Germany and at the DigestScience Congress in Lille, France.

All times in Eastern Time. HAIFA, Israel-- --Pluristem Therapeutics Inc. gab heute bekannt, dass sich in den dreimonatigen Nachbeobachtungsdaten des ersten jemals mit dem aus Plazenta gew... WEST POINT, Ga.-- --Knology, Inc.

Nov 17, 2009 - Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the ...

Pluristem Therapeutics Inc. today announced that it will present at the New England-Israel Life Sciences Summit at the Brandeis International Business School in Waltham, Mass.

BUYINS.NET, www.buyins.net, has reviewed the NYSE, NASDAQ, BX, CHX and NSX Daily Short Volume Report for Thursday, October 8th, 2009 and come to the following statistical conclusions.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Pluristem Therapeutics Inc. today announced, that on September 23, 2009, it filed its Annual Report on Form 10-K with the SEC, which included an audit report by the company's independent registered public accounting firm containing a going concern qualification.

Aug 11, 2009 - Pluristem Therapeutics Inc. today announced that the Phase I study for PLX-PAD in critical limb ischemia will be presented at the MSC2009 Regenerative Medicine and Adult Stem Cell Therapy conference.

ST. PAUL, Minn.-- --St. Jude Medical, Inc. will hold its quarterly conference call to discuss Second Quarter 2009 results on Wednesday, July 22, at 8:00 a.m. Eastern Time --Pluristem Therapeutics Inc.

Main Category: Cardiovascular / Cardiology Also Included In: Clinical Trials / Drug Trials Pluristem Therapeutics Inc.

Main Category: Stem Cell Research Also Included In: Clinical Trials / Drug Trials ; Regulatory Affairs / Drug Approvals Article Date: 17 Jun 2009 - 0:00 PDT Pluristem Therapeutics Inc.

In addition, Pluristem has already received approval from the Ethics Committee and, as previously announced, the US Food & Drug Administration had cleared the Company's Investigational New Drug application to initiate a similar trial in the United States.

Jun 10, 2009 - Pluristem Therapeutics Inc. , a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient cell therapy products for a variety of disorders, announced today that Mr.